Surpass 4 pdf
Rating: 4.7 / 5 (4114 votes)
Downloads: 41964
CLICK HERE TO DOWNLOAD
Therefore, the objective of SURPASSwas to compare the efficacy and safety of three doses of tirzepatide (5 mg,mg, andmg) versus glargine titrated to a fasting glucose of less than mg/dL in people with typediabetes and high cardiovascular risk inadequately controlled on oral glucose-lowering medications. The clinical endpoint was Background: In the SURPASStrial, the dual GIP and GLPreceptor agonist tirzepatide reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily insulin glargine in people with typediabetes inadequately controlled on oral diabetes treatments and with high cardiovascular risk. Methods The SURPASStrial showed that tirzepatide demonstrated greater reductions in HbA1c and lower incidence of hypoglycemia as compared with glargine among patients with inadequately controlled typediabetes and increased cardiovascular risk This pre-specific exploratory analysis of SURPASSevaluated the progression to pre-specified kidney endpoints between tirzepatide and titrated daily insulin glargine (iGlar). We aimed to compare the effects of typediabetes. The rate of line in kidney function and urinary albumin excretion were used as outcomes. Therefore, the objective of SURPASSwas to compare the efficacy and safety of three doses of tirzepatide (5 mg,mg, andmg) versus glargine titrated to Background In the SURPASStrial, the dual GIP and GLPreceptor agonist tirzepatide reduced HbA1c concentrations, bodyweight, and blood pressure more than titrated daily Background: In the SURPASStrial, the dual GIP and GLPreceptor agonist tirzepatide reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily Missing: pdf SURPASS(NCT) was a week study comparing the efficacy and safety of Mounjaromg (N=),mg (N=) andmg (N=) as monotherapy to placebo Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNTRandomized Clinical Trial Cardiology JAMA JAMA The SURPASStrial (number, NCT), which compared tirzepatide with insulin glargine, enrolled patients with increased cardiovascular risk, and the SURPASS-CVOT trial typediabetes.